Ask Questions (ASQ):Implementation of a Communication Intervention

Status Completed

Clinical Trial Summary

This clinical trial implements a communication intervention to improve patient-oncologist communication in the outpatient medical oncology setting. A communication brochure called the ASQ brochure may help patients prepare for the doctor visit by thinking through the questions that patients and patients' family want to ask the doctor.

Clinical Trial Description

Patient-centered communication is critical to providing high-quality care. In patient-provider clinical interactions, providers are responsible for several aspects of patient-centered communication. However, to reach the goal of providing the best possible treatments, patients should also actively participate by asking questions and expressing their concerns. Question prompt lists, simple lists of questions provided to patients before clinic visits to help them prepare for the appointment, have been tested in several medical contexts and patient populations, including among an underserved, minority population in Detroit, and have been shown to contribute to improved outcomes related to better communication quality. Using a RE-AIM framework, this descriptive, mixed methods, single-arm intervention study assesses the implementation of an evidence-based communication intervention (question prompt list), the "ASQ brochure". The ASQ brochure is designed to improve patient-oncologist communication and other outcomes by improving patient self-efficacy for managing patient-physician interactions. Investigators will recruit 225 patients and implement the ASQ brochure at seven Karmanos Cancer Center network sites. Participants are newly diagnosed patients with (Stages I-IV) cancer for which systemic therapy is likely a recommended treatment. ;

Study Design

Related Conditions & MeSH terms

Breast Neoplasms
Carcinoma, Ovarian Epithelial
Carcinoma, Renal Cell
Colorectal Neoplasms
Kidney Neoplasms
Lung Neoplasms
Ovarian Neoplasms
Prostatic Neoplasms
Stage II Bladder Cancer
Stage II Breast Cancer
Stage II Cervical Cancer
Stage II Colorectal Cancer
Stage II Lung Cancer
Stage II Ovarian Cancer
Stage II Prostate Cancer
Stage III Bladder Cancer
Stage III Breast Cancer
Stage III Cervical Cancer
Stage III Colorectal Cancer
Stage III Lung Cancer
Stage III Ovarian Cancer
Stage III Prostate Cancer
Stage IV Bladder Cancer
Stage IV Breast Cancer
Stage IV Colorectal Cancer
Stage IV Kidney Cancer
Stage IV Lung Cancer
Stage IV Ovarian Cancer
Stage IV Prostate Cancer
Urinary Bladder Neoplasms
Uterine Cervical Neoplasms

Clinical Trial Details

NCT number	NCT05025748
Study type	Interventional
Source	Barbara Ann Karmanos Cancer Institute
Contact
Status	Completed
Phase	N/A
Start date	August 25, 2021
Completion date	August 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01987726` - Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
Completed	`NCT01881230` - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)	Phase 2/Phase 3
Terminated	`NCT01918306` - GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer	Phase 1/Phase 2
Terminated	`NCT01705340` - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery	Phase 1
Terminated	`NCT01222377` - Endoscopic Breast Surgery in Treating Patients With Breast Cancer	N/A
Completed	`NCT00602043` - F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer	Phase 2
Completed	`NCT00425672` - ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment	Phase 1/Phase 2
Completed	`NCT00100750` - Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer	Phase 1/Phase 2
Completed	`NCT00244881` - A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)	Phase 2
Completed	`NCT00096109` - Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer	Phase 2
Completed	`NCT00096434` - Sorafenib in Treating Patients With Metastatic Breast Cancer	Phase 2
Completed	`NCT00057941` - Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer	Phase 2
Terminated	`NCT02892734` - Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer	Phase 2
Recruiting	`NCT03213041` - Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer	Phase 2
Completed	`NCT02015559` - Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus	Phase 2
Completed	`NCT02728596` - S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)	N/A
Completed	`NCT03364348` - 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer	Phase 1
Completed	`NCT02897375` - Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors	Phase 1
Completed	`NCT01672684` - Phase I: At-Home Support for Rural Women Using Group Video Calling	Phase 1
Terminated	`NCT01233505` - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors	Phase 1